Compare BRC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRC | CORT |
|---|---|---|
| Founded | 1914 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.7B |
| IPO Year | 2005 | 2001 |
| Metric | BRC | CORT |
|---|---|---|
| Price | $73.67 | $73.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.20 | ★ $96.50 |
| AVG Volume (30 Days) | 322.7K | ★ 1.0M |
| Earning Date | 05-15-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,144,698,000.00 | $761,407,000.00 |
| Revenue This Year | $7.36 | $26.08 |
| Revenue Next Year | $3.57 | $26.98 |
| P/E Ratio | $23.35 | ★ N/A |
| Revenue Growth | 5.86 | ★ 12.79 |
| 52 Week Low | $65.76 | $28.66 |
| 52 Week High | $99.29 | $91.00 |
| Indicator | BRC | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 33.44 | 80.24 |
| Support Level | $72.12 | $73.79 |
| Resistance Level | $80.39 | $79.89 |
| Average True Range (ATR) | 3.37 | 2.68 |
| MACD | -0.38 | 0.70 |
| Stochastic Oscillator | 2.71 | 91.88 |
Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.